Stay updated with breaking news from Nasdaq Immx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 172,200 shares, an increase of 71.7% from the September 30th total of 100,300 shares. Approximately 2.3% of the shares of the company are sold short. Based […]
Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 888 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Immix Biopharma to related businesses based on the strength of its valuation, risk, analyst recommendations, dividends, institutional ownership, profitability and earnings. Volatility and Risk […]
Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 975 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Immix Biopharma to related businesses based on the strength of its analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership. Volatility & Risk Immix Biopharma […]
Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) Director Melissa Jane Buchan purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was acquired at an average cost of $2.46 per share, with a total value of $49,200.00. Following the purchase, the director now directly owns 20,000 […]
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage...